News & Updates
Showing Oncology articles
Showing
Real-world data in Japan: 1L/2L palbociclib-ET effective in HR-positive/HER2-negative advanced breast cancer
Palbociclib combined with endocrine therapy (ET) is effective in hormone receptor (HR)–positive, HER2-negative advanced breast cancer (ABC) in both first-line (1L) and second-line (2L) settings in the real world, a multicentre observational study in Japan has shown.
Patritumab deruxtecan may improve survival in EGFR-mutated NSCLC
Treatment with patritumab deruxtecan (HER3-DXd) confers survival benefits on patients with epidermal growth factor receptor (EGFR)-mutated nonsmall-cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy, results of a phase I study have shown.
Could 15 years be the new 10 for repeat colonoscopy?
Adults who have tested negative for colorectal cancer (CRC) on initial colonoscopy and have no family history of CRC may only need to undergo a repeat screening after 15 years, according to a new Swedish study.
Olanzapine vs fosaprepitant: Which is better for CINV prevention?
Olanzapine appears to be just as effective as fosaprepitant, a neurokinin-1 receptor antagonist (NK1-RA), in controlling chemotherapy-induced nausea and vomiting (CINV) in patients with gynaecologic malignancies who were receiving carboplatin/paclitaxel chemotherapy every 3 weeks, a prospective study presented at SGO 2024 suggests. However, the former trumps the latter in terms of cost effectiveness.